Lucror Analytics

Lucror Analytics is a leading credit and ESG research specialist and a provider of technology solutions for differentiated fixed income strategies. Our roots are in bottom-up fundamental credit analysis with a specialization in high yield corporate credits from Europe, Asia and Latin America. We are one of few research specialists integrating ESG considerations with fundamental credit research through a dedicated ESG platform. Our ESG assessment covers five key criteria: Disclosure, E,S, & G Pillars, Controversies, ESG Impact on Credit and ESG Momentum.

Recognizing the importance and value-add of Factor Investing in fixed income, Lucror developed the Smart Quant Navigator (SQN), an intuitive platform that helps clients devise and implement factor-based strategies ranging from pure quant to active fundamental, with integrated ESG.

Our company has been at the forefront of developments in the fixed income markets, identifying opportunities and consistently delivering new products and value-adding solutions to clients. Lucror has close relationships with the largest and most reputable asset managers, family offices, hedge funds, investment and wealth managers globally.

High Yield Experts

Senior Credit Analyst, Lucror Analytics

Trung Nguyen

Senior Credit Analyst

Credit

Glenmark Pharmaceuticals’ Q2/19-20 results were encouraging, as both revenue growth and profitability improved relative to Q1. Even so, the H1 results trailed management's guidance for the whole year and the financial risk profile continued to weaken, albeit slightly. Liquidity is poor. The key risk to the business remains the prolonged and very steep price erosion for generic drugs in the US, the most profitable market. There could be pressure on Glenmark's ratings (BB- (negative) and BB (stable) from S&P and Fitch, respectively), as the company may have tripped S&P’s negative triggers.

  Glenmark Pharmaceuticals’ Q2/19-20 results were encouraging, as both revenue growth and profitability improved relative to Q1. Even so, the H1 results trailed management's guidance for the whole year and the financial risk profile continued to weaken, albeit slightly. Liquidity is poor.   The key risk to the business remains the prolonged and very steep price erosion for generic drugs in the US, the most profitable market.   There could be pressure on Glenmark's ratings (BB- (negative) and BB (stable) from S&P and Fitch, respectively), as the company may have tripped S&P’s negative triggers. 

Glenmark - Earnings Flash - Q2 FY 2019-20 Results - Lucror Analytics